OsteoSight Hip

by Naitive  · Based in United Kingdom → — Powering Orthopedic Care
Endocrinology Orthopedics Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

OsteoSight™ is an AI-driven software developed by Naitive Technologies to transform orthopedic care by enabling the opportunistic assessment of bone mineral density (BMD) from routine X-rays. It is specifically designed to analyze standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 years and older. The tool identifies cases at risk for low BMD, which is a key indicator of osteoporosis, a condition often undiagnosed until a fracture occurs.

By seamlessly integrating into existing orthopedic and radiology workflows, OsteoSight™ provides a notification in the form of a report to aid interpreting physicians in identifying patients with possible low BMD at the femoral neck. This early identification prompts a clinical assessment of bone health, supporting earlier interventions, improved surgical planning, and ultimately enhancing patient outcomes. The technology has received FDA 510(k) clearance (K251408) and was designated an FDA Breakthrough Device in 2023, with its diagnostic accuracy, reproducibility, and robustness validated in peer-reviewed research. OsteoSight™ aims to address the urgent unmet clinical need in osteoporosis management, allowing orthopedic practices to take a proactive role and potentially expand their services.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Opportunistic assessment of bone mineral density (BMD) from routine X-rays
  • Analyzes hip or pelvis X-rays in patients 50 years and older
  • Identifies cases at risk for low BMD
  • Provides a notification/report to aid interpreting physician
  • Integrates into existing orthopedic and radiology workflows
  • Validated in peer-reviewed research for diagnostic accuracy and reproducibility
  • AI-driven software for musculoskeletal health
  • Aids in earlier diagnosis and intervention for osteoporosis
  • Excludes unsuitable cases including incorrect body parts, metalwork, and unacceptable femur positioning

Use Cases

  • Early identification of patients at risk for osteoporosis
  • Opportunistic bone health assessment during routine X-rays for other clinical concerns
  • Streamlining referrals for comprehensive bone health assessment
  • Supporting earlier interventions and improved surgical planning
  • Expanding services and capturing ancillary revenue for orthopedic practices
  • Improving patient outcomes by reducing osteoporotic fractures

What Physicians Need to Know

Evidence Base
OsteoSight™ Hip leverages an AI-enabled algorithm to estimate bone mineral density (BMD) from routine hip and pelvic X-rays. The technology is designed to identify patients at risk of low BMD, which is a significant public health concern due to the high rates of undiagnosed osteoporosis. The tool's utility is particularly noted in settings where DXA accessibility is limited or not recently performed.
Clinical Validation Studies
Clinical performance assessment for OsteoSight™ Hip is based on a retrospective analysis of multi-center studies. The diagnostic accuracy, reproducibility, and robustness of OsteoSight™ were evaluated against dual-energy X-ray absorptiometry (DXA), the clinical gold standard for BMD assessment. The study found that the diagnostic accuracy for identifying patients at risk of low BMD had an Area Under the Receiver Operating Characteristic curve (AUROC) of 0.834 [0.789-0.880]. Specificity was 0.852 [0.783-0.930] and sensitivity was 0.628 [0.538-0.743], meeting pre-specified acceptance criteria. The pre-processing pipeline successfully excluded unsuitable cases, such as incorrect body parts, metalwork, and unacceptable femur positioning. The tool's reproducibility was demonstrated by consistent results from multiple X-ray images of the same individuals, showing an 84% observed agreement. Robustness was confirmed across different patient demographics, clinical confounders, and X-ray scanner hardware.
Clinical Workflow Integration
OsteoSight™ is designed for seamless integration into existing clinical workflows. It operates by processing standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 and older. The device provides a notification in the form of a report to aid radiologists and/or physician interpreters in identifying patients with possible low BMD at the femoral neck, prompting a clinical assessment of bone health. This opportunistic assessment uses X-rays already acquired for other clinical concerns, such as pain or falls. The report is delivered to the interpreting physician via a host integration platform.
Decision Audit Trail
While specific details about OsteoSight™ Hip's decision audit trail are not explicitly provided, general principles for orthopedic audit trails emphasize preserving history, supporting role-based accountability, and retrievability over time to meet HIPAA's integrity and documentation standards. An audit trail should show the sequence of actions, who performed them, and when, including intake, internal processing, communications, and delivery attempts. It should also include authority basis, validation outcome, requested versus fulfilled scope with exclusions and reasons, and a content manifest including imaging.
Physician Tip

OsteoSight™ Hip is an opportunistic assessment tool that can help identify patients at risk of low bone mineral density from routine hip and pelvic X-rays, especially when DXA is not readily available or recently performed. The tool provides a report to alert physicians about potential low BMD, prompting further clinical evaluation and a comprehensive fracture risk assessment. It is important to remember that OsteoSight™ is not intended to replace DXA and does not diagnose osteopenia or osteoporosis. Physicians should continue to follow recommended practices for screening and assessment, even in the absence of an OsteoSight™ report.

OsteoSight™ operates as an AI-enabled software as a Medical Device (SaMD) that integrates with a host integration platform. This platform facilitates the secure transfer of DICOM images and associated metadata from clinical imaging systems. The software can be installed in the cloud, potentially within the existing secured network of a clinical site, and consists of microservices deployed through container orchestration services like Docker. The generated reports can be sent back to the PACS for physician interpretation.

Details

Category Clinical Decision Support & Reference, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-based, with integration capabilities for clinical imaging systems (e.g., PACS) for secure DICOM image transfer.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Cleared AI-estimated

Naitive® Receives FDA 510(k) Clearance for OsteoSight™, AI-Enabled Opportunistic Bone Health Assessment. OsteoSight™ Receives FDA Breakthrough Device Designation.

Integrations
EHR Not specified
Specialties Endocrinology, Orthopedics, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-09-02K251408 510(k)OsteoSight™ Hip

What the Web Says

OsteoSight Hip (v1) by Naitive Technologies Ltd. is a medical device that received 510(k) clearance from the FDA on September 2, 2025. It was also part of the FDA's Breakthrough Devices Program, which aims to expedite the development and review of medical devices to provide timely access to patients and healthcare providers. As of the current date, detailed reviews and opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra are not readily available in the search results.

Overall: Mixed

Limitations

No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.

Based on reviews from: fda.gov, nyquistai.com

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OsteoSight Hip

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Naitive® Receives FDA 510(k) Clearance for OsteoSight™, AI-Enabled Opportunistic Bone Health Assessment
Naitive Technologies announced it received 510(k) clearance from the U.S. FDA for its flagship product, OsteoSight, an AI-enabled software for opportunistic assessment of bone mineral density (BMD) using standard X-rays. This clearance allows the technology to help identify patients at risk for low BMD earlier, improving outcomes and reducing the impact of osteoporosis.
2025-09
Orthopedic Design & Technology
Naitive Technologies Earns FDA Clearance for Bone Health Assessment Tool
Naitive Technologies' OsteoSight received FDA 510(k) clearance, enabling clinicians to assess low bone mineral density from routine hip or pelvis X-rays in patients 50 years and older. This AI-powered tool aims to help orthopedic practices proactively manage osteoporosis by identifying at-risk patients earlier.
2025-09
IGMPI
Naitive Technologies' OsteoSight Gains FDA Clearance for Early Osteoporosis Detection
UK-based Naitive Technologies secured FDA 510(k) clearance for OsteoSight, an AI-driven software that evaluates bone mineral density (BMD) using standard X-rays of the hip or pelvis in patients aged 50 and older. The tool aims to identify at-risk patients earlier and initiate timely interventions for osteoporosis.
2025-09
FDA.gov
OsteoSight™ Hip (v1) FDA 510(k) Clearance Letter
The U.S. Food and Drug Administration granted 510(k) clearance to Naitive Technologies Ltd. for its OsteoSight™ Hip (v1) device, classified as Radiology Software for Opportunistic Evaluation of Low Bone Mineral Density. The software is intended for use with standard anteroposterior radiographs of the hip or pelvis in patients aged 50 years and older to aid in identifying possible low bone mineral density.
2025-09
naitive.com
Naitive® and Utah Orthopaedics Launch Study on Opportunistic Bone Health Assessment in Clinical Workflows
Naitive Technologies partnered with Utah Orthopaedics to launch a research study using OsteoSight to assess the prevalence of low bone mineral density (BMD) in the local population. The study will also evaluate OsteoSight's estimated BMD in comparison to DXA BMD, the current gold standard for diagnosing osteoporosis.
2025-08
Osteoporosis International (via NIH.gov)
Diagnostic accuracy, reproducibility, and robustness of an AI-enabled opportunistic screening tool for low bone mineral density from hip and pelvic X-rays
This peer-reviewed study evaluated the diagnostic accuracy, reproducibility, and robustness of OsteoSight, an automated image analysis tool designed to identify low bone mineral density (BMD) from routine hip and pelvic X-rays. The results demonstrated that OsteoSight is accurate in identifying patients with low BMD, suggesting its utility as an opportunistic assessment tool.
2025-04
ITN Online
Naitive Technologies secures Innovate UK co-funding to expand osteoporosis screening technology to spine and chest X-rays
Naitive Technologies secured £334K co-funding from Innovate UK to increase the accessibility of its osteoporosis screening technology, OsteoSight, by incorporating spine and chest X-rays into its platform. Currently, OsteoSight can be used on hip and pelvis X-rays, and this expansion aims to reach an additional 40% of all X-rays performed.
2024-08
Orthoworld
Naitive Technologies and Heraeus Medical Collaborate to Characterize Bone Health and Fixation Methods in THA and TKA Patients
Naitive Technologies entered a research collaboration with Heraeus Medical and Sah Orthopaedic Associates to use OsteoSight to estimate the prevalence of low bone mineral density (BMD) in patients with an AP hip or pelvic X-ray who have undergone primary elective total hip arthroplasty (THA) or total knee arthroplasty (TKA).
2025-10

Videos

Product demos, reviews, and walkthroughs for OsteoSight Hip.

Loading videos...

View all on YouTube

Frequently Asked Questions

OsteoSight™ Hip is an AI-powered software that analyzes routine hip or pelvic X-rays of patients aged 50 and older to identify those at risk for low bone mineral density (BMD). It integrates seamlessly into existing orthopedic workflows by processing standard X-rays and providing a report to aid the interpreting physician in prompting a clinical assessment of bone health.
OsteoSight™ Hip helps in the earlier identification of patients with possible low BMD, which is crucial since osteoporosis is often underdiagnosed until a fracture occurs. This earlier detection allows for timely intervention, improved surgical planning, and potentially better patient outcomes by reducing the incidence of osteoporotic fractures.
OsteoSight™ Hip is an opportunistic assessment tool that identifies patients at risk of low BMD from routine X-rays, but it is not intended to replace DEXA scans, which remain the clinical gold standard for diagnosing osteopenia and osteoporosis. It aids in case finding, especially where DEXA accessibility is limited, prompting further evaluation with DEXA.
OsteoSight™ Hip is not intended to diagnose osteopenia or osteoporosis, nor can it be used to rule out low BMD. Variations in X-ray quality, such as patient positioning or equipment, could potentially influence the algorithm's performance and interpretation of results.
While OsteoSight™ Hip offers a unique AI-driven approach to opportunistic screening using routine X-rays, traditional methods for identifying patients at risk for low BMD primarily involve screening guidelines for at-risk individuals and subsequent DEXA scans. Other AI tools for opportunistic assessment of osteoporosis may exist, but OsteoSight is specifically designed to integrate into existing orthopedic workflows.
OsteoSight™ Hip received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2025 and was designated as an FDA Breakthrough Device in 2023.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-10 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.